Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 12122827 IL-21 polypeptides and targeted constructs

Patent 12122827 was granted and assigned to Asher Biotherapeutics on October, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Asher Biotherapeutics
Asher Biotherapeutics
0
Date Filed
April 26, 2023
0
Date of Patent
October 22, 2024
0
Patent Applicant
Asher Biotherapeutics
Asher Biotherapeutics
0
Patent Application Number
18307477
0
Patent Citations
‌
US Patent 8034326 IL-21 variants
0
‌
US Patent 8211420 Interleukin-21 variants with altered binding to the IL-21 receptor
0
‌
US Patent 8383367 IL-21 variant nucleic acids
0
‌
US Patent 8822653 Plasma kallikrein binding proteins
0
‌
US Patent 9447159 Immunoconjugates
0
‌
US Patent 9850310 CD123 binding agents and uses thereof
0
‌
US Patent 10202464 Immunoconjugates
0
‌
US Patent 10316104 Immunoconjugates
0
‌
US Patent 10538595 Multispecific antibody platform and related methods
0
‌
US Patent 11471490 T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
0
•••
Patent Inventor Names
Byong Kang
0
Henry C. Nguyen
0
Renee L. Greer
0
Yik Andy Yeung
0
Ivana Djuretic
0
David Liu
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12122827
0
Patent Primary Examiner
‌
Jeffrey Stucker
0
CPC Code
‌
C07K 2317/24
0
‌
C07K 16/40
0
‌
A61K 2039/505
0
‌
C07K 14/54
0
‌
A61P 35/00
0
‌
C07K 16/2815
0
‌
A61K 38/00
0

Find more entities like US Patent 12122827 IL-21 polypeptides and targeted constructs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.